Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.
Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.
Bausch Health (NYSE:BHC) reported results of its 2026 Annual Meeting of Shareholders held on May 19, 2026. All 10 director nominees were elected, including new director Eiry W. Roberts, M.D., who will chair the Science and Technology Committee.
Shareholders approved, on a non-binding basis, executive compensation, and confirmed PricewaterhouseCoopers LLP as auditor until the 2027 annual meeting, authorizing the board to set auditor remuneration. Final vote totals will be disclosed in a Form 8-K filing.
Bausch Health (NYSE:BHC) announced that CEO Thomas J. Appio and EVP/CFO Jean-Jacques Charhon will join a fireside chat at the RBC Capital Markets 2026 Global Healthcare Conference in New York City on May 20, 2026, at 9:30 a.m. U.S. ET.
A live audio webcast and replay will be available in the Investor Relations section of Bausch Health's website.
Bausch Health (NYSE:BHC) announced that management will participate in a fireside chat at the Barclays 30th Annual Leveraged Finance Conference in Austin, Texas on Tuesday, May 19, 2026 at 10:25 a.m. U.S. ET.
A live webcast and replay will be available on the company’s investor relations website.
Bausch Health (NYSE:BHC) reported Q1 2026 revenue of $2.52 billion, up 12% reported and 7% organic. GAAP net loss attributable to BHC was $1,423 million, driven by a $1,426 million goodwill impairment. Adjusted EPS was $0.78 (+32%) and adjusted EBITDA was $837 million (+27%). Bausch + Lomb revenue was $1.24 billion. The company reaffirmed full‑year 2026 revenue, adjusted EBITDA, and adjusted cash flow guidance. Larsucosterol Phase 3 remains on track and consolidated cash totaled $1.299 billion as of March 31, 2026.
Bausch Health (NYSE:BHC) and its dermatology unit Ortho Dermatologics launched Biafine® Skin Recovery Emulsion for U.S. consumers via select online channels on April 14, 2026. First developed in France in 1971, Biafine is a lightweight, clinically supported emulsion for dry, sensitive, or stressed skin.
The product is available directly to patients through select online retailers including Amazon, and dermatology practices can supply it via the Ortho Dermatologics Direct platform when recommended by a clinician.
Bausch Health (NYSE:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026.
The company will host a live conference call and webcast at 5:00 p.m. U.S. EDT the same day; materials and a replay will be available on the Investor Relations website prior to and after the call.
Bausch Health (NYSE:BHC) and Ortho Dermatologics announced the 2026 ASPIRE HIGHER Scholarship Program, awarding six students impacted by dermatologic conditions with scholarships of up to $10,000 each. Applications are open through June 10, 2026, and recipients will be notified in July 2026.
Eligible applicants include current or prospective students for the 2026–2027 academic year at two- or four-year colleges, universities, or advanced vocational/technical schools; three undergraduate and three graduate awards will be offered. Applicants must submit an essay and two letters of reference. More details at the program website.
Bausch Health (NYSE:BHC) and Solta Medical launched the Clear + Brilliant Touch laser in Canada following Health Canada approval on May 20, 2025. The dual-wavelength fractional laser expands Canadian access to customizable, low‑downtime skin resurfacing for multiple skin types and ages.
The System uses two handpieces (1440 nm and 1927 nm) with specific indications for wrinkles, dyschromia, pigmentation, texture and pore size, and is positioned as a year‑round, easy‑to‑use aesthetic option for physicians.
Bausch Health (NYSE:BHC) and OraPharma mark the 25th anniversary of ARESTIN (minocycline HCl) Microspheres, 1 mg, the only FDA‑approved locally applied antibiotic used adjunctively with scaling and root planing (SRP) for adult periodontitis. The product is supported by over two decades of clinical experience and recent commercial expansion into Canada and Puerto Rico.
The company emphasizes ongoing support for non‑surgical periodontal care and continued collaboration with the dental community.
Bausch Health (NYSE:BHC) reported Q4 2025 consolidated revenues of $2.80 billion (+9% reported, +6% organic) and full-year revenues of $10.27 billion (+7% reported, +5% organic). GAAP net loss for Q4 was $112 million; full-year GAAP net income was $157 million. Q4 adjusted EBITDA was $1.05 billion (up 13%); full-year adjusted EBITDA was $3.54 billion (up 7%). The company completed the China Solta acquisition, executed significant refinancing (including a $1.7B debt exchange) and provided 2026 guidance: revenues $10.625–$10.875B and adjusted EBITDA $3.875–$4.000B.